Certain capitalist economists accuse the National Institute for Health and Clinical Excellence of valueing the quality of human life too high . NICE judged "value for money" at a cost far higher than the NHS could afford.
The effectiveness of the drug, and its side-effects, are balanced with its cost to give a price per extra year of good health - called a Quality Adjusted Life Year (QALY).
In approximate terms, if the new treatment can deliver one QALY for £20,000 or less, then it is deemed cost-effective and heading for NHS approval. If the QALY costs up to £30,000, it may still be approved for NHS use by NICE.
The think tank The Kings Fund and City University, suggested that this £30,000 threshold was far too high when compared with how the rest of the NHS worked out which treatments to fund.
Some primary care trusts simply just pay £12000 in key areas such as circulatory disease per QALY .
Professor Nancy Devlin, from City University said "It's all about value for money... in the current NHS, where there is far less money to spend..."
The Glasgow & Edinburgh Branches Blog. Towards a better understanding of the world, in order to change it.
No comments:
Post a Comment